臓器移植におけるサイトメガロウイルス感染症

出版社： 日本医学館
著者：
発行日： 1997-05-14
分野： 臨床医学：外科  >  移植/人工臓器
ISBN： 9784890443444
電子書籍版： 1997-05-14 （第1版第1刷）
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,300 円(税込)

購入する

目次

  • 表紙
  • 執筆者一覧
  • 本書の刊行に寄せて
  • 序
  • 目次
  • PART1 CMV感染症の基礎知識
  • サイトメガロウイルスの名称と分類
  • ウイルス粒子 (ビリオンvirion)
  • CMVの増殖
  • CMVの感染
  • CMV感染症
  • 疫学
  • CMV感染症のウイルス学的診断法
  • 治療の指標
  • 抗ウイルス化学療法
  • おわりに
  • PART2 CMV感染症の診断法
  • CMV感染症の診断と定義
  • CMV感染症とその鑑別診断
  • 血清学的方法
  • 組織学的診断法
  • ウイルス分離培養
  • CMVゲノムの検出
  • CMVアンチゲネミア法による診断
  • 症例の検討
  • PART3 腎移植にけるCMV感染症
  • 移植患者の易感染性
  • 時期的にみた移植患者の感染症と治療
  • 腎移植後にみられるウイルス感染症
  • 臓器移植, 特に腎移植におけるCMV感染症の歴史
  • CMVの感染様式
  • CMV感染症の病態, 特に間質性肺炎
  • 移植後における間質性肺炎の発生機序とその治療
  • 症例の検討
  • CMV感染 (症) 予防と治療
  • PART4 骨髄移植におけるCMV感染症
  • 骨髄移植の原理
  • 歴史
  • 骨髄移植にみられるウイルス感染症
  • 感染様式
  • 骨髄移植における感染症の診断法
  • 病態
  • CMV感染症のリスク因子
  • 予防
  • 治療
  • PART5 肝移植における感染症
  • 歴史
  • 肝移植後にみられるウイルス感染症-CMV以外の感染症
  • 感染様式
  • 診断法
  • 病態
  • 予防
  • 治療
  • CMV感染のその影響
  • 索引
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

PART1 CMV感染症の基礎知識

P.17 掲載の参考文献
1) Mocarski ES:Cytomegaloviruses and their replication. Fields Virology. 3rd ed. (Fields BN, Knipe DM and Howley PM et al. eds.), Lippincott-Raven Publishers, Philadelphia, 1996, pp.2447-2492.
 
2) Schmolke S et al.:The dominant phosphoprotein pp 65 (UL 83) of human cytomegalovirus is dispensable for growth in cell culture. J. Virol. 69:5959-5968, 1996.
 
3) Monte PD et al.:Stably expressed antisense RNA to cytomegalovirus UL 83 inhibits viral replication. J. Virol. 70:7086-2094, 1996.
 
4) Michel D et al.:The UL 97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase. J. Virol. 70:6340-6346, 1996.
 
5) Compton T:Towaards a definition of HCMV entry pathway. Scand. J. Infect. Dis. Suppl., 99:30-32, 1995.
PubMed
6) 南嶋洋一:サイトメガロウイルス, 最新内科学大系 26:ウイルス感染症(井村裕夫, 尾形 悦郎, 高久史麿, 垂井清一郎・編, 齋藤 厚, 島田馨専門編集). 中山書店, 1994, pp.147-154.
 
7) Kondo K, Kaneshima H, Mocarski ES:Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc. Natl. Acad. Sci. USA 91:11879-11883, 1994.
PubMed
8) Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH:Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J. Gen. Virol. 72:2059-2064, 1991.
PubMed
9) Ibanez CE, Schrier R, Ghazal P et al:Human cytomegalovirus productively infects primary differentiated macrophages. J. Virol. 65:6581-6588, 1991.
PubMed
10) Fish KN, Stenglein SG, Ibanez C, Nelson JA:Cytomegalovirus persistence in macrophages and endothelial cells. Scand. J. Infect. Dis. 99:34-40, 1995.
 
11) Zaia JA:Epidemiology and pathogenesis of cytomegalovirus disease. Semin. Hematol. (Suppl.1) 27:5-10, 1990.
 
12) Ljungman P, Plotkin SA:Workshop on CMV disease;Definitions, Clinical severity scores, and new syndromes. Scand. J. Infect. Dis. Suppl.99:87-89, 1995.
 
13) Stagno S, Whitley RJ:Herpesvirus infection of pregnancy. Part I:Cytomegalovirus and Epstein-Barr virus infections. N. Engl. J. Med. 313:1270-1274, 1985.
PubMed
14) Grundy JE et al.:Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition? Lancet 2:996-999, 1987.
PubMed
15) Drew WL:Cytomegalovirus infection in patients with AIDS. Clin. Infect. Dis. 14:608-615, 1992.
PubMed
16) Kuppermann BD, Petty JG, Richman DD et al.:Correlation between CD 4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus related noninfectious retinal vasuculopathy in patients with acquired immnodeficiency syndrome. Amer. J. Ophthalmol. 115:575-582, 1993.
 
17) Peters BS, Beck EJ, Anderson S et al.:Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival. J. Infect. 23:129-137, 1991.
PubMed
18) 南嶋洋一, 峰松俊夫:ウイルス検査法-サイトメガロウイルス. 臨床とウイルス 23(Suppl.):131-136, 1995.
 
19) 峰松俊夫, 細田健治, 南嶋洋一:抗サイトメガロウイルス・ヒトモノクローナル抗体F (ab')2分画を用いた直接免疫ペルオキシダーゼ法による抗原陽性白血球検出法の基礎的検討. 感染症学雑誌 68:1278-1283, 1994.
 
20) The TH, van der Bij W, van der Berg AP et al.:Cytomegalovirus antigenemia. Rev. Inf. Dis. 12:S737-S744, 1990.
 
21) Field AK, and Biron KK:"The end of innocence" revisisited:Resistance of herpesviruses to antiviral drugs. Clin. Microbiol. Rev. 7:1-13, 1994.
PubMed
22) 藤崎智明・他:非血縁者間骨髄移植後に合併したganciclovir治療抵抗性cytomegalovirus肝炎に対するfoscarnet療法. 臨床血液 38:142-145, 1997.
 
23) Sasaki T et al:A case of progressive retinitis-encephalitis due to ganciclovir-resistant cytopmegalovirus associated with aplastic anemia. (submitted) .
 
24) Harada K et al.:Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both ganciclovir and cidofovir. Arch. Virol. 142:215-225, 1997.
PubMed
25) Griffiths PD, Emery VC:Cytomegalovirus. Clinical Virology (Richman DD, Whitley RJ, Hayden FG et al. eds.), Churchill Livingstone, New York, 1997, pp.445-470.
 

PART2 CMV感染症の診断法

P.34 掲載の参考文献
1) Farrugia E, Schwab TR:Management and prevention of cytomegalovirus infection after renal transplantation. Mayo Clin. Proc. 67:879-890, 1992.
PubMed
2) Rubin RH:Impact of cyomegalovirus infection on organ transplant recipients. Rev. Infect. Dis. 12 (Supple. 7):s754-s766, 1990.
 
3) 南嶋洋一:移植とサイトメガロウイルス. 今日の移植 4(5):483-487, 1991.
 
4) 高橋公太:腎移植におけるサイトメガロウイルス感染症. 今日の移植 6(5):507-516, 1993.
Medical*Online
5) 田辺一成, 高橋公太:感染症-特に間質性肺炎. 腎と透析 36(5):949-952, 1994.
 
6) Guerin C, Pozzetto B, Broyet C, Gaudin O, Berthowx F:Ganciclovir therapy of symptomatic cytomegalovirus infection in renal transplant recipients. Nephrol. Dial. Transplant. 4:906-910, 1989.
 
7) Dunn DS, Mayorai JL, Gillingham KJ, Loeffler CM, Brayman KL et al.:Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation 51:98-106, 1991.
 
8) Crumpacker CS:Ganciclovir. New. Engl. J. Med. 335:721-729, 1996.
PubMed
9) 八木沢隆, 高橋公太, 沢田登起彦, 石川暢夫, 尊田和徳・他:Shell-vial法を用いたサイトメガロウイルス感染症の早期診断に関する検討. 移植 27(4):540-547, 1992.
Medical*Online
10) Paya CV, Wold AD, Smith TF:Detection of cytomegalovirus infections in specimens other than urine by the shell vial assay and conventional tube cell culture. J. Clin. Microbiology 25:755-757, 1987.
 
11) Jespersen DJ, Drew WL, Gleaves CA, Meyers JD, Warford AL, Smith TF:Multisite evaluation of a monoclonal antibody reagent (Syva) for rapid diagnosis of cytomegalovirus in the shell vial assay. J. Clin. Microbiology 27:1502-1505, 1989
 
12) Arens M, Owen J, hagerty CM, Reed CA, Storch GA:Optimizing recovery of cytomegalovirus in the shell vial culture procedure. Diagn. Microbiol. Infect. Dis. 14:125-130, 1991.
PubMed
13) Middeldorp JM, Jongsma J. The TH:J. Clin. Microbiol. 20:763, 1984.
PubMed
14) Morris DJ, Fox AJ, Klapper PE:Diagnosis of cytomegalovirus infection in cyclosporin-treated renal allograft recipients. J. Med. Virol. 32:124-127, 1990.
PubMed
15) 栄鶴義人:サイトメガロウイルス感染症の診断. 臨床病理 42:1234-1239, 1994.
Medical*Online
16) Freeman F, Gould FK, McMaster A:Management of cytomegalovirus antibody negative patients undergoing heart transplantation. J. Clin. Pathol. 43:373-376, 1990.
 
17) Storch GA, Buller RS, Bailey TC, Ettinger NA, Langlois T, Gaudreault-Keener, Welby PL:Comparison of PCR and pp65 antigenemia assay with quantitative shell vial culture for detection of cytomegalovirus in blood leukocytes from solid-organ transplant recipients. J. Clin. Microbiol. 32:997-1003, 1994.
PubMed
18) Wunderli W, Kagi NK, Grunter E, Auracher JD:Detection of cytomegalovirus in peripheral leukocytes by different method. J. Clin. Microbiol. 27:1916-1917, 1989.
 
19) Gleaves CA, Smith TF, Shuster EA, Pearson GR:Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen. J. Clin. Microbiol. 19:917-919, 1984.
 
20) Van den Berg AP, Baan der Gij W, Van Son WJ, Anema J, van der Giessen M et al.:Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation-A report of 130 consecutive patients. Transplantation 48 (6):991-995, 1989.
 
21) The TH, Van der Gij W, Van den Berg AP, Van der Giessen M, Weits J et al.:Cyomegalovirus antigenemia. Rev. Infect. Dis. 12 (Suppl.7):s737-s744, 1990.
 
22) The TH, van der Ploeg M, Van den Berg AP, Vlieger AM, Van der Giessen M et al.:Direct detection of cytomegalovirus in peripheral blood leukocytes A review of the antigenemia assay and polymerase chain reaction. Transplantation 54(2):193-198, 1992.
PubMed
23) 権藤久司, 原田実根:サイトメガロウイルス(CMV)感染症と抗原血症. 臨床科学 30:967-977, 1994.
 
24) 田辺一成, 高橋公太, 尊田和徳・他:Antigenemia法による腎移植後サイトメガロウイルス感染症の早期診断. 今日の移植 8:229-235, 1995.
Medical*Online
25) Tanabe K, Takahashi K, Koyama I, Sonda K, Fuchinomue S et al.:Early diagnosis of CMV syndrome after kidney transplantation:Comparison between CMV antigenemia and PCR assay. Transplant. Proc. 28 (3):1508-1510, 1996.
 
26) 田辺一成, 小山一郎, 高橋公太・他:腎移植後のサイトメガロウイルス(CMV)感染症に対する各種検査法の臨床的有用性について-CMVアンチゲネミアアッセイ, PCR法, 抗体価測定法, シェルバイアル法の比較検討. 今日の移植 9:649-654, 1996.
 
27) Boland GJ, De Weger RA, Tilanus MGJ, Ververs C, Bosboom-Kalsbeek K, De Gast GC:Detection of cytomegalovirus (CMV) in granulocytes by polymerase chain reaction compared with the CMV antigen test. J. Clin. Microbiol. 30:1763-1767, 1992.
 
28) Bitsch A, Kirchner H, Dennin R, Hoyer J, Fricke L, Steinhoff J, Sack K, Bein G:The long persistence of CMV DNA in the blood of renal transplant patients after recovery from CMV infection. Transplantation 56:108-113, 1993.
 
29) 南嶋洋一:サイトメガロウイルス(CMV)の特徴:CMV, CMV感染, CMV感染症. 今日の移植 6:495-499, 1993.
 
30) Griffiths PD:Cytomegalovirus:In Principles and Practice of Clinical Virology. 2nd Edition. Edited by Zuckerman AJ, Banatvala, JE, Pattison JR, Chichester, England, John Wiley & Sons, 1990, p69-102.
 
31) Drew WJ et al.:Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J. Infect. Dis. 163:716-719, 1991.
 
32) Masuho Y et al.:Human monoclonal antibodies neutralizing human cytomegalovirus. J. Gen. Virol. 68:1457-1461, 1987.
PubMed
33) Grefte et al.:Cytomegalovirus antigenemia assay:Identification of the viral antigen as the lower matrix protein pp65. J. Infect. Dis. 166:683-684, 1992.
PubMed
34) Gerna G et al:Human cytomegalovirus infection of the major leukocyte subpopulations and evidence for initial viral replication in polymorphonuclear leukocytes from viremic patients. J. Infect. Dis. 166:1236-1244, 1992.
PubMed
35) Kurihara T, Hayashi J, Matsuoka T, Ito A:HCMV pp65 antigenemia assay using indirect alkaline phosphatase staining method. Biomedical. Research 16:125-129, 1995.
 
36) Taylor-Wiedeman J et al.:Monocyts are a major site of persistance of human cytomegalovirus in peripheral blood mononuclear cells. J. Gen. Virol. 72:2059-2064, 1991.
 
37) 小山一郎, 田辺一成, 高橋公太, 尊田和徳, 徳本直彦・他:サイトメガロウイルス感染症の診断および治療にアンチゲネミア法が有用であった3例. 移植 31(3):234-238, 1996.
 

PART3 腎移植にけるCMV感染症

P.75 掲載の参考文献
1) Ho M:Cytomegalovirus. Plenum Publishing Corporation, New York, 1982.
 
2) Takahashi K, Teraoka S, Yagisawa T, Ota K, Kobayashi S et al.:Effect of human interferon-β on viral pneumonitis in kidney transplant recipients, Herpes viruses and virus chemotherapy (Kono R, Nakajima A) , Excerpta Medica, Amsterdam, 1984, pp.297-298.
 
3) 高橋公太:臓器移植と感染-腎移植を中心に, 外科領域感染症(酒井克治編), 医薬ジャーナル社, 大阪, 1986, pp.249-273.
 
4) 高橋公太:腎移植患者と感染, 化学療法と感染(上田 泰, 斎藤 篤編), 東京医学社, 東京, 1992, pp.127-147.
 
5) 高橋公太:臓器移植における感染症. 総合臨床 43:1371-1376. 1994.
 
6) 高橋公太, 八木沢隆, 東間 紘, 寺岡 慧, 太田和夫・他:Ciclosporin使用腎移植症例における感染症の分析. 日泌尿会誌 80:175-184, 1989.
 
7) 鳴海福星, 東間 紘, 高橋公太, 中沢速和, 太田和夫・他:腎移植患者のウイルス感染症について. 移植 16:121-123, 1981.
 
8) 高橋公太, 寺岡 慧, 八木沢隆, 渕之上昌平, 太田和夫・他:腎移植患者ciclosporin使用例におけるウイルス感染症の分析. 移植 20(suppl):490-500, 1986.
 
9) Takahashi K, Yagisawa T, Teraoka S, Tanabe T, Ota K et al.:Infectious diseases in 450 kidney transplant recipients treated cyclosporine in a single center. Transplant. Proc. 21:1563-1566, 1989.
 
10) Rubin RH:The problem of cytomegalovirus infection in transplantation. Progress in transplantation (Morris PJ et al. ed.) , Chutrchill Livingstone. London, 1984, pp.89-114.
 
11) Hill RB, Rowlands DT, Rifkind D:Infectious pulmonary disease in patients receiving immunosuppressive therapy for organ transplantation. N. Engl. J. Med. 271:1021, 1964
PubMed
12) Kanich RE, Craighad JE:Cytomegalovirus infection and cytomegalic inclusion disease in renal homotransplant recipients. Amer. J. Med. 40:874-881, 1966.
 
13) Hedley-White ET, Craighead JE:Generalized cytomegalic inclusion disease after renal homotransplantation. N. Engl. J. Med. 272:473, 1965.
 
14) Simmons RL, Lopez C, Balfour H, Rattazzi LC, Najarian JS:Clinical virological correlation in renal transplant recipients. Ann. Surg. 180:623-634, 1974.
 
15) 沼崎義夫:小児科臨床とサイトメガロウイルス. 小児科 19:633-638, 1978.
 
16) Van der Bij W, Sshirm JS, Torensma R, van Son WJ, Tegzess AM et al.:Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J. Clin. Microbil. 26:2531-2535, 1988.
 
17) The TH, van der Bij W, van der Berg AP, Vlieger AM, van der Giessen M et al.:Cytomegalovirus antigenemia. Rev. Infect. Dis. 12 (suppl 7):s737-s744, 1990.
 
18) The TH, van der Ploeg M, van der Berg AP, Vlieger AM, van der Giessen, et al.:Direct detection of cytomegalovirus in peripheral blood leukocytes-A review of the antigenemia assay and polymerase chain reaction. Transplantation 54:193-198, 1992.
 
19) 高橋公太:サイトメガロウイルス肺炎. 化学療法の領域 2:202-210, 1986.
 
20) 高橋公太, 八木沢隆, 尊田和徳, 山口 裕, 太田和夫・他:移植後におけるcytomegalovirus間質性肺炎の発生メカニズムと治療に関する考察. 今日の移植 5:287-291, 1992.
Medical*Online
21) 高橋公太, 尊田和徳, 太田和夫:腎移植後における間質性肺炎の発生メカニズムとその治療. 腎と透析 34:231-237, 1993.
 
22) Grundy JE, Shanley JD, Griffiths PD:Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition? Lancet 2:996-999, 1987.
PubMed
23) 南嶋洋一:ウイルス感染における感染防御機能. 臨床とウイルス 18:30-34, 1990.
 
24) 田中和生, 古賀泰裕, 木村元喜, 野本亀久雄:サイトメガロウイルス(CMV)持続感染が宿主生体防御機能系に与える影響と免疫抑制剤の選択. 移植 28(総会臨時号):146, 1993.
 
25) Tanaka K, Koga Y, Zang X, Nomoto K et al.:Murine cytomegalovirus-assocciated pneumonitis in the lungs free of the virus. J. Clin. Invest. 94:1019-1025, 1994.
 
26) 田中和正, 梅沢和夫, 阿部貴弥, 岡田恵子, 古賀泰裕・他:サイトメガロウイルス(CMV)感染症の肺病変の成立における活性酸素の役割. 移植 30(総会臨時号):163, 1995.
 
27) 田中和正, 古賀泰裕:移植後サイトメガロウイルス肺炎の病因についての基礎的検討. 今日の移植 9:27-34, 1996.
 
28) 八木沢隆, 横田俊彦, 君川正昭, 高橋公太, 太田和夫・他:サイトメガロウイルスによる単核症, 肝炎を合併した腎移植の1例. 移植 25:209-215, 1990.
 
29) 高橋公太, 高山裕史, 早坂勇太郎, 太田和夫, 小林茂保・他:腎移植後のウイルス感染症にヒトβ型インターフェロン(HuIFN-β)を使用した1症例. 腎と透析 14:341-345, 1983.
 
30) 高橋公太, 寺岡 慧, 八木沢隆, 水口 潤, 太田和夫・他:腎移植後のウイルス感染症におけるヒトβ型インターフェロン(HuIFN-β)の効果(第2報). 腎と透析 17:243-251, 1984.
 
31) Takahashi K, Teraoka S, Yagisawa T, Ebihara K, Ota K et al.:Treatment of cytomegalovirus infection in kidney transplant patients with human interferon-β and ganciclovir. The Biology of the interferon system (Kawada Y et al. ed.), Local organizing committee of the fifth annual meeting of the interferon research, 1989, pp.103-108.
 
32) 海老原和正, 高橋公太, 八木沢隆, 山口 裕, 太田和夫・他:Ganciclovirが有効であった腎移植後のCytomegalovirus nephropathyの一症例. 感染症学雑誌 63:644-648, 1989.
 
33) 高橋公太, 海老原和正, 太田和夫:腎移植患者におけるサイトメガロウイルス感染の予防と治療. 日本臨床 47:459-465, 1989.
Medical*Online
34) Takahashi K, Teraoka S, Yagisawa T, Fuchinoue S, Ota K et al.:Effect of human interferon-β on life-threatening viral pnumonitis in kidney transplant recipients. Transplant. Proc. 19:4089-4095, 1987.
 
35) Smee DF, Martin JC, Verheyden JPH, Mattthews TR:Antiherpesvirus activity of the acyclic nucleocide 9-(1, 3-dihydro-2-propoxymethyl) guanine. Antimicrob. Agents Chemother. 23:676-682, 1983.
 
36) Collaborative DHPG treatment study group:Treatment of serious cytomegalovirus infections with 9-(1, 3-dihydroxy-2-propoxymethi) guanine in patients with AIDS and other immunodeficiencies. N. Engl. J. Med. 314:801-805, 1986.
 
37) Erice A, Jordan MC, Chance BA, Fletcher C, Balfour HH:Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA 257:3082-3087, 1987.
 
38) 八木沢隆, 鈴木万里, 佐藤純彦, 高橋公太, 太田和夫・他:サイトメガロウイルス感染による十二指腸潰瘍・出血 間質性肺炎を合併した死体腎移植の1例. 移植 27:586-593, 1992.
Medical*Online
39) 高橋公太編集, 太田和夫監修:新しい免疫抑制剤-抗リンパ球モノクローナル抗体-. 医歯薬出版株式会社, 東京, 1991, pp 1-133.
 
40) Takahashi K, Teraoka S, Ota K, Kosaki M:The Japanese interferon study (JISG) has established the efficacy of human interferon-β for serious CMV pneumonitis in kidney recipients. Transplant. Int. 5 (suppl):133-137, 1991.
 
41) 高橋公太, 石橋道男, 吉村了勇, 八木沢隆, 太田和夫・他:腎移植後の急性拒絶反応に対するBMA 031の臨床効果. 今日の移植 4:659-666, 1991.
 
42) 高橋公太:サイトメガロウイルス感染症. 感染症 22:77-84, 1992.
 
43) 高橋公太:臓器移植における感染症. 総合臨床 43:1371-1376, 1994.
 
44) 権藤久司, 原田実根:移植症例への輸血. 医学のあゆみ 165:401-404, 1993.
Medical*Online
45) Patel R, Snydman DR, Rubin RH, Ho M, Paya CV et al.:Cytomegalovirus prophylax-is in solid organ transplant recipients. Transplantation 61:1279-1289, 1996.
 

PART4 骨髄移植におけるCMV感染症

P.99 掲載の参考文献
1) Thomas ED, Storb R, Clift RA, Fefer A, Johnson L et al.:Bone-marrow transplantation. N. Engl. J. Med. 292:832-843, 895-902, 1975.
 
2) Powles RL, Clink HM, Spence D, Moregenstern G, Watson JG et al.:Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation. Lancet i:327-329, 1980.
 
3) Storb R, Deeg HJ, Whitehead J et al.:Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N. Engl. J. Med. 314:729-735, 1986.
PubMed
4) Hows J, Bradley BA, Gore S, Downie T, Howard M et al:Prospective evaluation of unrelated donor bone marrow transplantation. Bone Marrow Transplantation 12:371-380, 1993.
PubMed
5) Reisner Y, Kapoor N, Kirkpatric D et al.:Transplantation for acute leukemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet ii:327-331, 1981.
 
6) Kato S, Yabe H, Yabe M, Kimura M, Ito M et al.:Studies on transfer of varicellazoster-virus specific T cell immunity from bone marrow donor to recipient. Blood 75:806-809, 1990.
 
7) Noel DR, Witherspoon RP, Storb R, Atkinson K, Doney K et al.:Does graft-versushost disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation on 56 long-term survivor. Blood 51:1087-1105, 1978.
 
8) 加藤俊一:CMV感染症とCMV陰性血液製剤の適応. 新輸血医学(伊藤和彦他編), 1993, p366-368.
 
9) Winston DJ, Huang E-S, Miller MJ, Lin C-H, Ho WG et al.:Molecular epidemiology of cytomegalovirus infections associated with bone marrow transplantation. Ann. Intern. Med. 102:16-20, 1985.
PubMed
10) Meyers JD, Flournoy N, Thomas ED:Cytomegalovirus infection and specific cellmediated immunity after marrow transplant. J. Infect. Dis. 142:816-824, 1980.
PubMed
11) Miller W, Flynn P, McCullough J et al.:Cytomegalovirus infection after bone marrow transplantation:an association with acute graft-v-host disease. Blood 67:1162-1167, 1986.
PubMed
12) Wingard JR, Mellitis ED, Sostrin MB et al.:Interstitial pneumonitis after allogeneic bone marrow transplantation. Nine-year experience at a single institution. Medicine67:175-186, 1988.
 
13) Meyers JD, Flournoy N, Thomas ED:Risk factors for cytomegalovirus infection after human marrow transplantation. J. Infect Dis. 153:478-488, 1986.
PubMed
14) Bowden RA, Sayers M, Flournoy N et al.:Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N. Engl. J. Med. 314:1006-1010, 1986.
PubMed
15) Winston DJ, Ho WG, Lin C-H et al.:Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann. Intern. Med. 106:12-18, 1987.
PubMed
16) Sullivan KM, Kopecky KJ, Jocom J et al.:Immunomodulatory and anti-microbialefficacy of intravenous immunoglobulin in bone marrow transplantation. N. Engl. JMed. 323:705-712, 1990.
 
17) De Witte, Schattenberg A, van Dijk BA, Galama J, Olthuis H et al.:Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation byusing leukocyte-poor random blood products from cytomegalovirus unscreened bloodbank donors. Transplantation 50:964-968, 1990.
 
18) Bowden RA, Fisher LK, Rogers K, Cays M, Meyers JD:Cytomegalovirus(CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infectionand disease after marrow transplant. J. Infect. D. 164:483-487, 1991.
 
19) Bowden RA, Slichter SJ, Sayers MH, Mori M, Cays MJ et al.:Use of leukocyte depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 78:246-250, 1991.
PubMed
20) Miller WJ, McCullough J, Balfour Jr HH et al.:Prevention of cytomegalovirus infection following bone marrow transplantation:a randomized trial of blood product screening. Bone Marrow Transplant. 7:227-234, 1991.
 
21) Meyers JD, Reed EC, Shepp DH et al.:Acyclovir for prevention of cytomegalovirusinfection and disease after allogeneic marrow transplantation. N. Engl. J. Med. 318:70-75, 1988.
 
22) Schmidt GM, Horak DA, Niland JC et al.:A randomized controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infections in recipients of allogeneic bone marrow transplants. N. Engl. J. Med. 324:1005-1011, 1991.
PubMed
23) Goodrich JM, Mori M, Gleaves CA et al.:Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N. Engl. J. Med. 325:1601-1607, 1991.
PubMed
24) Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch BA et al.:Prevention of cytomegalovirus disease after allogeneic marrow transplant by ganciclovir prophylaxis. Ann. Intern. Med. 118:173-178, 1993.
 
25) Gregory WW, Menugus MA:Practical protocol for cytomegalovirus isolation:use of MRC-5 cell monolayers incubated for 2 weeks. J. Clin. Microbial. 17:605-609, 1983.
 
26) Swenson PD, Kaplan MH:Rapid detection of cytomegalovirus in cell culture by indirect immunoperoxidase staining with monoclonal anti-body to an early nuclear antigen. J. Clin. Microbil. 21:669-673, 1985.
 
27) Hsia K, Spector DH, Lawrie J, Spector SA:Enzymatic amplification of human cytomegalovirus sequences by polymerase chain reaction. J. Clin. Microbial. 27:1802-1809, 1989.
 
28) van der Bij W, Torensma R, van Son WJ et al.:Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes. J. Med. Virol. 25:179-188, 1988.
PubMed
29) Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD:Cytomegalovirusantigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 80:1358-1364, 1992.
PubMed
30) Stover DE, Zaman MB, Jajdu SI, Lange M, Gold J et al.:Broncho-alveolar lavage in the diagnosis of diffuse pulmonary infiltrates in the immunosuppressed host. Ann. Intern. Med. 101:1-7, 1984.
 
31) McDonald GB, Sharma P, Hackman RC, Meyers JD, Thomas ED:Esophageal infections in immunosuppressed patients after marrow transplantation. Gastroenterology 88:1111-1117, 1985.
PubMed
32) Jacobson MA, Mills J:Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS) . Ann. Intern. Med, 108:585-594, 1988.
PubMed
33) Zaia JA, Lang DJ:Cytomegalovirus infection of the fetus and neonate. Neurol. Clin. North. Am. 2:387-410, 1984.
 
34) Kapasi K, Rice GPA:Cytomegalovirus infection of peripheral blood mononuclear cells:effects on interleukin-1 and-2 production and responsiveness. J. Virol. 62:3603-3607, 1988.
 
35) Quinan GV, Kirmani N, Rook AH et al.:Cytotoxic T cells in cytomegalovirus infection:HLA restriction T lymphocyte and non T lymphocyte cytotoxic responsescorrelate with recovery from cytomegalovirus in bone marrow recipients. N. Engl. J. Med. 307:7-13, 1982.
 
36) Meyers JD, Fluornoy N, Thomas ED:Nonbacterial pneumonia after allogeneic marrow transplantation. A review of ten years'experience. Rev. Infect. Dis. 4:1119-1132, 1982.
 
37) Zaia JA:Epidemioly and pathogenesis of cytomegalovirus disease. Semin. Hematol. 27:5-10, 1990.
 
38) Weiner RS, Bortin MM, Gale RP et al.:Interstitial pneumonitis after bone marrow transplantation:assessment of risk factors. Ann. Intern. Med. 104:168-175, 1986.
PubMed
39) Grundy JE, Shanley JD, Shearer GM:Augmentation of graft-versus-host reaction by cytomegalovirus infection resulting in interstitial pneumonitis. Transplantation 39:548-553, 1985.
PubMed
40) Bostrom L, Ringden O, Gratama JW, Jacobsen N, Zawwn F, Nilsson B:The impact of pretransplant herpes virus serology on acute and chronic graft-versus-host disease. Transplant. Proc. 22:206-207, 1990.
 
41) Lonnqvist B, Ringden O, Wahren B, Gahrton G, Lundgren G:Cytomegalovirus infection associated with and preceeding chronic graft-versus-host disease. Transplantation 38:465-468, 1984.
 
42) 矢部みはる, 矢部普正, 満田るみ, 小松田光真, 加藤俊一・他:同種骨髄移植後のサイトメガロウイルス感染症発症の要因と予防. 移植 24:493-497, 1989.
Medical*Online
43) de Witte T, Schattenberg A, van Dijk BA, Galama J, Olthuis H et al.:Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation 50:964-968, 1990.
PubMed
44) Meyers JD, Leszczynski J, Zaia J et al.:Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann. Intern. Med. 98:442-446, 1983.
PubMed
45) O' Reilly RJ, Reich L, Gold J et al.:A randomized trial of intravenous hyperimmune globulin for the prevention of cytomegalovirus (CMV) infections following marrow transplantation:preliminary results. Transplant. Proc. 15:1405-1411, 1983.
 
46) Kubanek B, Ernst P, Ostendorf P et al.:Preliminary data of a controlled trial of intravenous hyperimmune globulin in the prevention of cytomegalovirus infection in bone marrow transplant recipients. Transplant. Proc. 17:468-469, 1985. 47) Winston DJ, Ho WG, Lin GH et al.:Intravenous immune globulin for prevention ofcytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann. Intern. Med. 106:12-18, 1987.
 
48) Sullivan KM, Kopecky KJ, Jacom J et al.:Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N. Engl. J. Med. 323:705-712, 1990.
 
49) Meyers JD, Reed EC, Shepp DH et al.:Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N. Engl. J. Med. 318:70-75, 1988.
PubMed
50) Gluckman E, Lotsberg J, Devergie A, Zhao XM, Melo R et al.:Prophylaxis of herpesinfections after bone-marrow transplantation by oral acyclovir. Lancet 2:706-708, 1983.
PubMed
51) Atkinson K, Downs K, Golenia M et al.:Prophylactic use of ganciclovir in allogeneic bone marrow transplantation;absence of clinical cytomegalovirus infection. Br. J. Hematol. 79:57-62, 1991.
 
52) Winston DJ, Ho WG, Bartoni K et al.:Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann. Intern. Med. 118:179-184, 1993.
PubMed
53) Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR:Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant:correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83:1971-1979, 1994.
PubMed
54) Reusser P, Gambertoglio JG, Lilleby K, Meyers JD:Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J. Infect. Dis. 166:473-479, 1992.
PubMed
55) Boland GH, Vlieger AM, Ververs C, de Gast GC:Evidence for transfer of cellular and humoral immunity to cytomegalovirus from donor to recipient in allogeneic bonemarrow transplantation. Clin. Exp. Immunol 88:506-511, 1992.
 
56) Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME et al.:Restoration of viral immunity in immunodeficient humans by adoptive transfer of T cell clones. Science257:238-241, 1992.
 
57) Kato S, Yabe H, Yabe M, Kimura M, Ito M et al.:Studies on transfer of varicellazoster-virus specific T-cell immunity from bone marrow donor to recipient. Blood 75:806-809, 1990.
 
58) Plotkin SA, Furukawa T, Zygraich N, Huygelen D:Candidate cytomegalovirus strain for human vaccination. Infect. Immun. 12:521-527, 1975.
 
59) Gonczol E, Ianacone J, Ho W, Starr S, Meignier B et al.:The isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine 8:130-136, 1990.
PubMed
60) Kraemer KG, Neiman PE, Reeves WC, Thomas ED:Prophylactic adenine arabinoside following marrow transplantation. Transplant. Proc. 10:237-240, 1978.
PubMed
61) Meyers JD, McGuffin RW, Neiman PE, Singer JW, Thomas ED:Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumoniaafter marrow transplantation. J. Infect. Dis. 141:555-562, 1980.
PubMed
62) Meyers JD, McGuffin RW, Bryson YJ, Cantell K, Thomas ED:Treatment of cytomegalovirus pneumonia after marrow transplant with combined vidarabine and human leukocyte interferon. J. Infect. Dis. 146:80-84, 1982.
PubMed
63) Meyers JD, Day LM, Lum LG, Sullivan KM:Recombinant leukocyte A interferon for the treatment of serious viral infection after marrow transplant:a phase I study. J. Infect. Dis. 148:551-556, 1983.
PubMed
64) Winston DJ, Ho WG, Schroff RW, Champlin RE, Gale RP:Safety and tolerance of recombinant leukocyte A interferon in bone marrow transplant recipients. Antimicrob. Agents. Chemother. 23:846-851, 1983.
PubMed
65) Wade JC, Hintz M, McGuffin RW, Springmeyer SC, Connor JD et al.:Treatment of cytomegalovirus pneumonia with high dose acyclovir. Am. J. Med. 73:249-256, 1982.
 
66) Wade JC, McGuffin RW, Springmeyer SC, Newton B, Singer JW et al.:Treatment of cytomegalovirus pneumonia with high dose acyclovir and human leukocyte interferon. J. Infect. Dis. 148:557-562, 1983.
PubMed
67) Shepp DH, Newton BA, Meyers JD:Intravenous lymphoblastoid interferon and acyclovir for treatment of cytomegalovirus pneumonia. J. Infect. Dis. 150:776-777, 1984.
PubMed
68) Shepp DH, Dandliker PS, de Miranda P et al.:Activity of 9-[2-hydroxyl-1-(hydroxymethyl)ethoxymethyl] guanine in the treatment of cytomegalovirus pneumonia. Ann. Intern. Med. 103:368-372, 1985.
 
69) Winston DJ, Ho WG, Bartoni K et al.:Ganciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunosuppressed patients. Rev. Infect. Dis. 10 (suppl. 3):s547-s553, 1988.
PubMed
70) Erice A, Jordan MC, Chace BA, Fletcher C, Chinnock BJ et al.:Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA 257:3082-3087, 1987.
PubMed
71) Wilson EJ, Medearis DN Jr, Hansen LA, Rubin RH:9-(1-3-dihydroxy-2-propoxymethyl) guanine prevents death but not immunity in murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice. Antimicrob. Agents Chemother. 31:1017-1020, 1987.
 
72) Reed EC, Bowden RA, Dandliker PS, Meyer JD:Treatment of cytomegalovirus (CMV) pneumonia in bone marrow transplant (BMT) recipients (PTS) with ganciclovir (GCV) and CMV immunoglobulin (CMV-IG) . Blood 70 (suppl. 1):313a, 1987.
 
73) Bratanow A, Ash RC, Turner P et al.:The use of 9-(1, 3-dihydroxy-2-propoxymethyl) guanine (ganciclovir, DHPG) and intravenous immunoglobulin (IVIG) in the treatment of serious cytomegalovirus (CMV) infections in thirty-one allogeneic bone marrow transplant (BMT) patients. Blood 70 (suppl. 1):302a, 1987.
 
74) Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD:Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann. Intern. Med. 109:783-788, 1988.
PubMed
75) Emanuel D, Cunningham I, Jules-Elysee K et al.:Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann. Intern. Med. 109:777-782, 1988.
PubMed
76) Schmidt GM, Kovacs A, Zaia JA et al.:Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 46:905-907, 1988.
PubMed
77) Ljungman P, Engelhard D, Link H et al.:Treatment of interstitial pneumonitis dueto cytomegalovirus with ganciclovir and intravenous immune globulin:experience of European Bone Marrow Transplant Group. Clin. Infect. Dis. 14:831-835, 1992.
 

PART5 肝移植における感染症

P.122 掲載の参考文献
1) Colonna JO, Winston DL, Brill JE et al.:Infectious complications in liver transplantation. Arch. Surg. 23:360-364, 1988.
 
2) Paya CV, Hermans PE, Wiesner RH et al.:Cytomegalovirus hepatitis in liver transplantations. Prospective analysis of 93 consecutive orthotopic liver transplantations. J. Infect. Dis. 160:752-758, 1989.
PubMed
3) Sayage LH, Gonwa TA, Goldstein RM et al.:Cytomegalovirus infection in orthotopic liver transplantation. Transpl. Int. 2:96-101, 1989.
PubMed
4) Stratta RJ, Shaefer MS, Markin RS et al.:Clinical patterns of cytomegalovirus disease after liver transplantation. Arch. Surg. 124:1443-1450, 1989.
PubMed
5) Singh N, Dummer JS, Kusne S et al.:Infections with cutomegalovirus and other herpes viruses in 121 liver transplant recipients:Transmission by donated organ and the effect of OKT3 antibodies. J. Infect. Dis. 158:124-131, 1988.
 
6) Kusne S, Dummer S, Singh et al.:Infections after liver transplantation:An analysis of 110 consecutive cases. Medicine 67:132-143, 1988.
 
7) Ascher NNL, Stock PG, Bungardner GL et al.:Infection and rejection of primary hepatic transplant in 93 consecutive patients with triple immunosuppressive therapy. Surg. Gynecol. Obstet. 167:474-484, 1988.
 
8) Paya CV, Hermans PE, Washington JA et al.:Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantation. Mayo Clin. Proc. 64:555-564, 1989.
PubMed
9) Rifkind D, Marchioro T, Scneck K, Hill RB Jr:Systemic fungal infection complicating renal transplantation and immunosuppressiontherapy. Am. J. Med. 43:28-38, 1967.
 
10) Stratta RJ:Clinical patterns of cytomegalovirus infection after solid-organ transplantation. Transplant. Proc. 25:15-21, 1993.
PubMed
11) Wiesner RH, Marin E, porayko MK et al.:Advances in teh diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation. Gastroenterol Clin. North. Am. 22:351-366, 1993.
 
12) Canadian Multicenter Transplant Surgery Group:A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N. Engl. J. Med. 309:809-815, 1983.
 
13) Peterson PK, Balfour HH, Fryd DS et al.:Risk factors in the development of cytomegalovirus-related pneumonia in renal transplant recipients. J. Infect. Dis. 148:1121, 1983.
PubMed
14) Winston DJ, Wirin D, Shaked A, Busutil R:Randomized comparison of ganciclovir and high-dose acyclovir for long term cytomegalovirus prophylaxis in liver-transplant recipient. Lancet 346:69-74, 1995.
 
15) Kevin P:High The antimicrobial activities of cyclosporine, FK506, and Rapamycin. Transplantation 57:1689-1700, 1994.
 
16) Canadian Multicenter Transplant Study Group:A randomized clinical trial of cyclosporine in cadaveric renal transplantaion:analysis at three years. N. Engl. J. Med. 314:1219-1225, 1986.
 
17) Ferguson RM, Rynasiewicz JJ, Sutherland DER, Simmons RL, Najarian JS:Cyclosporine. A in renal transplantation:a prospective randomized trial. Surgery 92:175-182, 1982.
 
18) Kim JH, Perfect JR:Infection and cyclosporine. Rev. Infect. Dis. 2:677-690, 1989.
 
19) McMaster P, Haynes IG, Michael J et al.:Cyclosporine A in renal transplantation:a prospective randomized trial. Transplant. Proc. 15:2523-2527, 1983.
 
20) Najarian JS, Strand M, Fryd DS et al.:Comparison of cyclosporine versus azathioprine-antilymphocyte globulin in renal transplantation. Transplant. Proc. 15:2463-2468, 1983.
 
21) Sommer G, Ferguson RM:Mismatched living, related donor renal transplantation:a prospective randomized study. Surgery 98:267-274, 1985.
 
22) Ho M, Wajszcauk CP, Hardy A et al.:Infections in kidney, heart, and liver transplant recipients on cyclosporine. Transplant. Proc. 15:2768-2772, 1983.
 
23) Bia MJ, Andiam W, Gaudio K et al.:Effect of treatment with cyclosporine versus azathiopurine on incidence and severity of cytomegalovirus infection posttransplantation. Transplantation 40:610-614, 1985.
 
24) Alessiani M, Kusne S, Fung JJ et al.:CMV infection in liver transplantation under cyclosporine or FK506 immunosuppression. Transplant. Proc. 23:3035-3037, 1991.
PubMed
25) Rifkind D, Starzl TE, Marchioro TL, Waddel WR, Rowlans DT et al.:J. AM. Med. Ass. 189:808-812, 1964.
 
26) Hedley-White ET, Craighead JE:Generalized cytomegalic inclusion disease after renal homotransplantation. New Engl. J. Med. 272:473-475, 1965.
 
27) Hill RB, Rowland DT, Rifkind D:Infectious pulmonary disease in patients receiving immunosuppressive therapy for organ transplantation. New Engl. J. Med. 271:1021-1027, 1964.
 
28) Patel R, Snydman DR, Rubin RH, Ho M, Pescovitz M et al.:Cytomegalovirus prophylaxisis in solid organ transplantation. Transplantation 61:1279-1289, 1996.
 
29) Martin FM, Manez R, Linden P et al.:A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 58:779-785, 1994.
 
30) Saliba F, Eyraud D, Samuel D et al.:Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients. Transplant. Proc. 25:1444-1445, 1993.
PubMed
31) Green M, Reyes J, Nour B et al.:Randomized trial of gancyclovir followed by high dose oral acyclovir vs. gancoclovir alone in the prevention of cytomegalovirus disease in pediatric liver transplant recipients:preliminary analysis. Transplant. Proc. 26:173-174, 1994.
PubMed
32) Cohen AT, O'Grady JG, Sutherland S, Sallie R, Tan K-C, Williams R:Controlled trial of prophylactic versus therapeutic use of ganciclovir in liver transplantation in adults. J. Med. Virol. 40:5-9, 1993.
 
33) Nakazato PZ, Burns W, Moore P, GArcia-Kennedy R, Cox K, Esquivel C:Viral prophylaxis in hepatic transplantation:preliminary report of a randomized trial of acyclovir and ganciclovir. Transplant. Proc. 25:1935-1937, 1993.
PubMed
34) Singh N, Yu VL, Mietes L et al.:High-dose acyclovir compared with short courgae preemptive therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann. Intern. Med. 120:375-381, 1994.
 
35) Stratta RJ, Shaefer MS, Cushing KA et al.:A randomized prospective trial of acyclovir and immune globlin prophylaxis in liver transplant receiving OKT3 therapy. Arch. Surch. Surg. 127:55-64, 1992.
 
36) Haagsma EB, Klompmaker IJ, Grond J et al.:Herpes virus infection after orthotopic liver transplantation. Transplant. Proc. 19:4054-4056, 1987.
 
37) Dummer JS, Erb S, Breinig MK et al.:Infection with human immuno deficiency virus in the Pittsburg transplant population:A study of 583 donors and 1043 recipients, 1981-1986. Transplatation 47:134-140, 1989.
 
38) Lucy MR, Graham DM, Martin P et al.:Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut 33:1390-1396, 1992.
 
39) Todo S, Demetris AJ, Van Thiel D et al.:Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 49:1155-1158, 1991.
 
40) Michaels MG, Green M, Wald ER, Starzl TE:Adenovirus infection in pediatric liver transplant recipients. J. Infect. Dis. 165:170-174, 1992.
PubMed
41) Fung J, Starzl T:Prophylactic use of OKT3 in liver transplantation:A review. Dig. Dis. Sci. 36:1427-1430, 1991.
PubMed
42) Gorensek MJ, Carey WD, Vogt D, Goormastic M:A multivariate analysis of risk factors for cytomegalovirus infection in liver-transplant recipients. Gastroenterol. 98:1326-1332, 1990.
 
43) Martin M:Antiviral prophylaxis for CMV infection in liver transplantation. Transplant. Proc. 25 (Suppl.4):10-14, 1993.
 
44) Thung SN, Gerber MA:Cytomegaloviral hepatitis vs Herpes Simplex hepatitis. (in) Differential diagnosi in pathology:Liver Disorders (eds. Thung SN, Gerber MA), New York, Igakushoin, 1995, p100-101.
 
45) The TH, van den Bij W, van den Berg AP, van den Giessen M et al.:Cytomegalovirus antigenemia. Rev. Infect. Dis. 12 (Suppl.):735-744, 1990.
 
46) 猪股裕紀洋, 上本伸二, 田中紘一・他:サイトメガロウイルス(CMV)抗原血症を指標とした生体部分肝移植後のCMV感染症の早期発見とモニタリング. 今日の移植 7:481-486, 1994.
 
47) Sano K, Tanaka K, Uemoto S et al.:Cytomegalovirus infection in living related liver transplantation:Rapid diagnosis by human monoclonal antibody staining of blood leukocytes. Transplant. Science 4:105-111, 1994.
 
48) Koskinen PK, Nieminen MS, Mattila SP, Hayry PJ, Lauten-schlager IT:The correlation between symptomatic CMV infection and CMV antigenemia in heart allograft recipients. Transplantation 55:547-551, 1993.
 
49) Meyers JD, Ljungman P, Fischer LD:Cytomegalovirus exretion as a predictor of disease aftel marrow transplantation:importance of cytomegalovirus viremia. J. Infect. Dis. 162:373-380, 1990.
 
50) Badley AD, Patel R, Portela DF:Prognosotic significance and risk factors of untreated cytomegalovirus viremia in liver transplant recipients. T. J. Infect. Dis. 173:446-449, 1996.
 
51) The TH, van den Berg AP, van son WJ et al.:Monitoring for cytomegalovirus after organ transplantation:A clinical perspective. Transplant. Proc. 25 (Suppl.4):5-9, 1995.
 
52) Drouret E, Colimon R, Michelson S et al.:Monitoring levels of human cytomegalovirus DNA in blood ater liver transplantation. J. Clin. Microbiology 33:389-394, 1995.
 
53) Sido B, Hofman WJ, Otto G et al.:Cytomegalovirus infection of the liver graft early after transplantation:Incidence and clinical relevance. Transplant. Proc. 25:2671-2672, 1993.
 
54) Bronsther O, Makowka L, Jaffe R et al.:Occurrence of cytomegalovirus hepatitis in liver transplant patients. J. Med. Viol. 24:423-434, 1988.
 
55) Alessiani M, Kusne S, Fung JJ et al.:CMV infection in liver transplantation under cyclosporine or FK506 immunosuppression. Transplant. Proc. 23:3035-3037, 1991.
PubMed
56) van den Verg AP, van Son WJ, Haagsma EB et al.:Predicition of recurrent cytomegalovirus disease after treatment with gancyclovir in solid-organ transplants. Transplantation 55:847-851, 1993.
 
57) Kowdley KV, Fawaz KA, Kaplan MM:Extrahepatic biliary stricture associated with cytomegalovirus in a liver transplantation. Transplant. Int. 9:161-163, 1996.
 
58) Adler SP:Immunoprophylaxis against cytomegalovirus disease. Scand. J. Infect. Dis. 99:105-109, 1996.
 
59) Bell R, Sheil AGR, McDonald JA et al.:The role of CMV immune prophylaxis in patient at risk of primary CMV infection following orthotopic liver transplantation. Transplant. Proc. 21:3781-3782, 1989.
 
60) Dussaix E, Wood C:Cytomegalovirus infection in pediatric liver recipients:Avirologic survey and prophylaxis with CMV immunoglobulin and early DHPG treatment. Transplantation 48:272-274, 1989. Arch. Surg. 127:55-64, 1992.
 
61) Stratta RJ, Shaefer MS, Cushing KA et al.:Successful prophylaxis of cytomegalovirus disease after primary CMV exposure in liver transplant recipients. Transplantation 51:90-97, 1991.
PubMed
62) Mor E, Meyer BR, Yagmur O et al.:High-dose acyclovir and intravenous immune globulin reduce the incidence of CMV disease after liver transplantation. Transpl. Int. 8:152-156, 1995.
 
63) Marrtin M, Manez R, Linden P et al.:A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipient. Transplantation 58:779-785, 1994.
 
64) Paya CV, Hermans PE, Smith TF et al.:Efficacy of gancyclovir in liver and kidney transplant recipients with severe cytomegalovirus infection. Transplantation 46:229-234, 1988.
PubMed
65) Harrison MA, DeGirolami PC, Jenkins RL, Hammer SM:Ganciclovir therapy of severe cytomegalovirus infection in solid organ transplant recipients. Transplantation 46:82-88, 1988.
 
66) Lewis RA, Carr LM, Doyle K et al.:Combination foscarnet and ganciclovir therapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS:The Cytomegalovirus Retreatment trial. Arch. Ophthalmol 114:23-33, 1996.
 
67) Paya CV, Wiesner RH, Hermans PE et al.:Risk factors of Cytomegalovirus and severe bacterial infections folowing liver transplantation:A prospective time-dependent analysis. J. Hepatolo. 18:185-195, 1992.
 
68) Rubin RH:Infectious disease problems, In (ed. Maddrey WC) , Transplantation of the Liver. New York, Elsevier, 1988.
 
69) Stratta RJ, Shaefeer MS, Markin RS et al.:Cytomegalovirus infection and disease after liver transplantation:An over view. Dig. Dis. Sci. 37:673-688, 1992.
 
70) Rook RH:Interactions of cytomegalovirus with the human immune system. Rev. Infect. Dis. 10 (Suppl 3):460-467, 1988.
 
71) Fujinami RS, Nelson JA, Walker L et al.:Sequence homology and immunologic crossreactivity of human cytomegalovirus with HLA-DR beta chain:A means for graft rejection and immunosuppression. J. Viol. 62:100-105, 1988.
 
72) Grundy JE, Ayles HM, McKeating JA et al.:Enhancement of class I HLA antigen expression by cytomegalovirus infection:Role and amplification of the virus. J. Med. Virol. 25:483-495, 1988.
PubMed
73) Von Xillebrand E, Pettersson E, Ahonen J et al.:CMV infection, class II antigen expression and human kidney allograft rejection. Transplantation 42:364-367, 1986.
 
74) Arnold JC, Portmann BC, O'Gray JG et al.:Cytomegalovirus infection persisit in the liver graft in the vanishing bile duct syndrome. Hepatology 16:285-292, 1992.
 
75) O'Grady JG, Alexander GJ, Sutherland S et al.:Cytomegalovirus infection and donor/recipient HLA antigens:Independent co-factors in pathgenesis of vanishing bile duct syndromes after liver transplantation. Lancet 2:302-305, 1990.
 
76) Paya CV, Wiesner RH, HermansPE et al.:Lack of association between cytomegalovirus infection or HLA matching and the vanishing bile duct syndrome after liver transplantation. Hepatology 16:66-70, 1992.
PubMed
77) Melnick JL, Adam E, DeBakey ME:Possible role of cytomegalovirus infection in atherogenesis. JAMA 263:2204-2207, 1990.
PubMed
78) Grattan MT, Moreno-Cabral CE, Starnes VA:Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 261:3561-3566, 1989.
PubMed

書評

最近チェックした商品履歴

Loading...